Matthew Meyerson

307.6k total citations · 28 hit papers
287 papers, 58.9k citations indexed

About

Matthew Meyerson is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matthew Meyerson has authored 287 papers receiving a total of 58.9k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Molecular Biology, 91 papers in Pulmonary and Respiratory Medicine and 84 papers in Cancer Research. Recurrent topics in Matthew Meyerson's work include Cancer Genomics and Diagnostics (68 papers), Lung Cancer Treatments and Mutations (64 papers) and RNA modifications and cancer (40 papers). Matthew Meyerson is often cited by papers focused on Cancer Genomics and Diagnostics (68 papers), Lung Cancer Treatments and Mutations (64 papers) and RNA modifications and cancer (40 papers). Matthew Meyerson collaborates with scholars based in United States, Germany and Canada. Matthew Meyerson's co-authors include Gad Getz, Michael J. Eck, Pasi A. Jänne, Heidi Greulich, Bruce E. Johnson, Stacey Gabriel, Titus J. Boggon, William R. Sellers, Rameen Beroukhim and Craig H. Mermel and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Matthew Meyerson

277 papers receiving 57.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 3.2k citations Susumu Kobayashi, Titus J. Boggon et al. profile →
Discovery and saturation analysis of cancer genes across 21 tumour types

2014 2.1k citations Levi A. Garraway, Todd R. Golub et al. profile →
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

2011 2.0k citations Matthew Meyerson, Rameen Beroukhim et al. profile →
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

2001 2.0k citations William G. Richards, Stefano Monti et al. Proceedings of the National Academy of Sciences profile →
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

2013 1.9k citations Matthew Meyerson et al. profile →
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

2008 1.6k citations Cai‐Hong Yun, Kristen E. Mengwasser et al. Proceedings of the National Academy of Sciences profile →
hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization

1997 1.5k citations Matthew Meyerson et al. profile →
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

2011 1.4k citations Adam J. Bass, Matthew Meyerson et al. profile →
Pan-cancer patterns of somatic copy number alteration

2013 1.2k citations Andrew D. Cherniack, Stacey Gabriel et al. profile →
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

2008 1.2k citations Takeshi Shimamura, Geoffrey I. Shapiro et al. profile →
Absolute quantification of somatic DNA alterations in human cancer

2012 1.1k citations Barbara A. Weir, Rameen Beroukhim et al. profile →
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

2005 1.1k citations Levi A. Garraway, Mark A. Rubin et al. profile →
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

2007 904 citations Cai‐Hong Yun, Titus J. Boggon et al. profile →
Inhibition of telomerase limits the growth of human cancer cells

1999 862 citations William C. Hahn, Matthew Meyerson et al. profile →
Advances in understanding cancer genomes through second-generation sequencing

2010 798 citations Matthew Meyerson, Stacey Gabriel et al. profile →
A family of human cdc2-related protein kinases.

1992 791 citations Matthew Meyerson et al. profile →
Chromothripsis from DNA damage in micronuclei

2015 787 citations Joshua M. Francis, Matthew Meyerson et al. profile →
Recurrent BRAF mutations in Langerhans cell histiocytosis

2010 742 citations Gayane Badalian‐Very, Jo‐Anne Vergilio et al. Blood profile →
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

2011 732 citations Nikhil Wagle, Michael F. Berger et al. Journal of Clinical Oncology profile →
Commensal Microbiota Promote Lung Cancer Development via γδ T Cells

2019 711 citations Matthew Meyerson et al. profile →
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.

1994 705 citations Matthew Meyerson et al. profile →
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

2007 598 citations Jeffrey A. Engelman, Takeshi Shimamura et al. Cancer Research profile →
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

2019 536 citations Alison M. Taylor, Matthew Meyerson et al. profile →
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

2005 536 citations Heidi Greulich, Pasi A. Jänne et al. profile →
Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus

2004 504 citations Jeffrey C. Lee, Matthew Meyerson et al. profile →
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

2013 422 citations Juliann Chmielecki, David A. Frank et al. profile →
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

2009 310 citations Rameen Beroukhim, Mark A. Rubin et al. Cancer Research profile →

Peers

Countries citing papers authored by Matthew Meyerson

Since Specialization

Citations

This map shows the geographic impact of Matthew Meyerson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Meyerson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Meyerson more than expected).

Fields of papers citing papers by Matthew Meyerson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Meyerson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Meyerson. The network helps show where Matthew Meyerson may publish in the future.

Co-authorship network of co-authors of Matthew Meyerson

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Meyerson. A scholar is included among the top collaborators of Matthew Meyerson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Meyerson. Matthew Meyerson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines	Cancer Research	Zhouwei Zhang, Lior Golomb et al.	26
2	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry	Clinical Cancer Research	Yusuke Koga, Hanbing Song et al.	58
3	RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade	Molecular Cancer Therapeutics	Bruno Bockorny, Maria Rusan et al.	43
4	Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor	Cancer Discovery	Xiaoyang Zhang, Peter S. Choi et al.	85
5	MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma	Cancer Research	Xinyuan Lu, Nir Peled et al.	49
6	Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy	Molecular Cancer Research	Hugh Gannon, Nathan O. Kaplan et al.	19
7	Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1 , NF2 , CDKN2A , and CUL1 in Malignant Pleural Mesothelioma	Cancer Research	Guangwu Guo, Juliann Chmielecki et al.	229
8	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC	Cancer Research	Jeremy H. Tchaicha, Esra A. Akbay et al.	30
9	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer	Cancer Research	Mohamed E. Abazeed, Drew Adams et al.	90
10	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer	Clinical Cancer Research	Takeshi Shimamura, Samanthi A. Perera et al.	131
11	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling breakdown →	Journal of Clinical Oncology	Nikhil Wagle, Michael F. Berger et al.	732
12	High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing	Cancer Discovery	Nikhil Wagle, Michael F. Berger et al.	384
13	Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers	Cancer Discovery	Hiu Wing Cheung, Jinyan Du et al.	110
14	Recurrent BRAF mutations in Langerhans cell histiocytosis breakdown →	Blood	Gayane Badalian‐Very, Jo‐Anne Vergilio et al.	742
15	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP breakdown →	Proceedings of the National Academy of Sciences	Cai‐Hong Yun, Kristen E. Mengwasser et al.	1564
16	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling	Cancer Research	Susumu Kobayashi, Takeshi Shimamura et al.	98
17	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor	Cancer Research	James V. Alvarez, Heidi Greulich et al.	206
18	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer	Cancer Research	Sven Perner, Francesca Demichelis et al.	388
19	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis	Cancer Research	Xiaojun Zhao, Barbara A. Weir et al.	242
20	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy breakdown →	Science	J. Guillermo Paez, Pasi A. Jänne et al.	7539

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact